Several studies have shown that inhibition of IL-6 enhances the therapeutic efficacy of α-PD-L1 therapy in melanoma, colorectal cancer, pancreatic cancer and hepatocellular carcinoma 45-48. This evidence concerns the gene IL6 and melanoma.